CDXS News and Press, Codexis Inc. From 11/06/19

Image source: The Motley Fool. Codexis   (NASDAQ: CDXS) Q3 2019 Earnings Call Nov 05, 2019 , 4:30 p.m. ET Operator Continue reading

Codexis, Inc. (CDXS) Q3 2019 Earnings Conference Call November 05, 2019, 04:30 PM ET Company Participants Bruce Voss - MD, LHA, IR John Nicols - President and CEO Ross Taylor - CFO Conference Call Participants Brandon Couillard - Jefferies & Co. Matt Hewitt - Craig-Ha...

Codexis (NASDAQ: CDXS ): Q3 Non-GAAP EPS of $0.04 beats by $0.09 ; GAAP EPS of $0.01 beats by $0.10 . More news on: Codexis, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Total revenues rose 29% to $21.9 million driven by strength in R&D, product, and CodeEvolver ® licensing revenues Eleven customers each contributed at least a quarter million dollars in revenue Conference call begins at 4:30 pm Eastern time today REDWOOD CITY, Calif...

REDWOOD CITY, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will participate in four upcoming investment conferences: 10 th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 12, ...

REDWOOD CITY, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report third quarter 2019 financial results after market close on Tuesday, November 5, 2019.  Codexis management will hold an investment c...

REDWOOD CITY, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, assembled approximately 150 top scientists in protein engineering to discuss recent progress and future direction in a forum held last week in Palo Alto, Calif. S...

BioMarin Pharmaceutical ( BMRN -0.5% ) has submitted an application to UK regulators seeking signoff to launch a Phase 1/2 clinical trial evaluating a single administration of BMN 307 in patients with phenylketonuria (PKU), a rare inborn error of metabolism that causes the amino acid phe...

Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, is contributing resources and expertise to communicate protein engineering’s vast potential at SynBioBeta’s Global Synthetic Biology Summit in San Francisco, Oct. 1–3. SynBioBeta is a prominent network o...

REDWOOD CITY, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will present at the 2019 Cantor Fitzgerald Global Healthcare Conference on Friday, October 4 at 12:00 p.m. Eastern time (9:00 a.m. Pacific ...